CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...